Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cystic fibrosis colonopathy.

J D Lloyd-Still1, D W Beno, R M Kimura

  • 1Rush Medical College, Department of Gastroenterology and Nutrition, Rush Presbyterian-St. Lukes Medical Center, 1725 Harrison Street, Chicago, IL 60612, USA.

Current Gastroenterology Reports
|September 12, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

TNF-alpha increases sensitivity to LPS in chronically catheterized rats.

American journal of physiology. Heart and circulatory physiology·2001
Same author

Ursodeoxycholic acid ameliorates ibuprofen-induced enteropathy in the rat.

Journal of pediatric gastroenterology and nutrition·2001
Same author

Endotoxin-induced reduction in biliary indocyanine green excretion rate in a chronically catheterized rat model.

American journal of physiology. Gastrointestinal and liver physiology·2001
Same author

Staphylococcal enterotoxin B potentiates LPS-induced hepatic dysfunction in chronically catheterized rats.

American journal of physiology. Gastrointestinal and liver physiology·2001
Same author

The effects of high-dose ibuprofen and pancreatic enzymes on the intestine of the rat.

Journal of pediatric gastroenterology and nutrition·1999
Same author

Pancreatic enzymes and fibrosing colonopathy.

Lancet (London, England)·1999

Fibrosing colonopathy, a serious condition linked to high-dose pancreatic enzymes, caused over 60 global cases before guidelines were enforced. Its distinct features include colon strictures and fibrosis, with unknown causes.

Area of Science:

  • Gastroenterology
  • Pediatric Gastroenterology
  • Clinical Pathology

Background:

  • A novel disease, fibrosing colonopathy, emerged in 1994, associated with excessive pancreatic enzyme administration.
  • Over 60 worldwide cases were documented prior to the implementation of enzyme dosage guidelines.
  • Predisposing factors included young age, prior intestinal surgery, meconium ileus equivalent, and concurrent use of H2 blockers, corticosteroids, and DNase.

Purpose of the Study:

  • To describe the clinical and pathological features of fibrosing colonopathy.
  • To identify predisposing factors and associated conditions.
  • To differentiate fibrosing colonopathy from other intestinal diseases.

Main Methods:

  • Review of clinical case data.

Related Experiment Videos

  • Analysis of pathological findings from affected patients.
  • Comparison with features of Crohn's disease and ischemic bowel disease.

    • Main Results:

    • Abnormal findings included foreshortened colon, strictures, submucosal fibrosis, ascites, and liver nodular hyperplasia.
    • Histologic examination revealed eosinophilia, mild cryptitis, epithelial regeneration, and muscularis mucosa disruption.
    • The condition's features are distinct from, yet share similarities with, Crohn's disease and ischemic bowel disease.

    Conclusions:

    • Fibrosing colonopathy is a distinct clinicopathological entity linked to pancreatic enzyme therapy.
    • The precise pathogenic mechanisms underlying fibrosing colonopathy remain to be elucidated.
    • Understanding these features is crucial for differentiating it from other bowel pathologies.